Sign in
CompletedPhase 1

Valacyclovir in Neonatal Herpes Simplex Virus Disease

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1
People taking part
7 people enrolled
Started
1 Jul 2021
Ended
24 Jul 2024
Type of study
Interventional
Treatments tested
  • Valacyclovir
Record updated
24 June 2025

Who can take part

Age
2 weeks to 12 weeks
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Signed informed consent from parent(s) or legal guardian(s)
  • Confirmation of HSV infection from surface culture/PCR, skin lesion culture/PCR, blood PCR, or CSF PCR (performed at UAB Virology lab)
  • ≥34 weeks gestational age at birth
  • Weight at study enrollment is ≥ 2000 grams
  • Receiving intravenous acyclovir, prescribed by the patient's physician for ≤ 14 days
  • ≤ 42 days of age at initiation of parenteral acyclovir
  • Creatinine ≤ 1.2

Who cannot take part

  • Current receipt of other investigational drugs
  • Major congenital anomaly that in the site investigator's opinion may impact drug metabolism or the patient's volume of distribution
  • Evidence of immunosuppression (HIV infected, immune deficiencies, etc.)
  • Any condition that, in the opinion of the investigator, would place the subject at an unacceptable injury risk or that may interfere with successful study completion
  • Creatinine of > 1.2 prior to initiation of valacyclovir
  • > 42 days of age at initiation of parenteral acyclovir
  • Imminent demise
  • Concern for parental/guardian compliance

Where in United States

  • University of Alabama/Children's of AlabamaBirmingham, United States

About the trial

What the trial wants to find out

This is an open-label, single center, pharmacokinetic (PK) study to assess valacyclovir pharmacokinetics and pharmacodynamics in neonates and compare to the pharmacokinetics and pharmacodynamics of the standard of care treatment dose of intravenous acyclovir. 6 (up to 10 infants) with virologically confirmed neonatal herpes simplex virus (HSV) disease who meet all inclusion/exclusion criteria will be enrolled in the study. Study duration is 5 years. Primary objective is to define the pharmacokinetics of valacyclovir and assess its safety in neonates 2-12 weeks of age who are ≥ 34 weeks gestation.

The group in the trial

  • Neonatal HSV disease requiring suppressive therapyOther group

    All subjects enrolled in the study will receive 2 (up to 7) days of valacyclovir 20 mg/kg every 8 hours after completion of standard of care treatment course with acyclovir.

    Treatment: Valacyclovir

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of the Pharmacokinetics and Pharmacodynamics of Valacyclovir in Neonates With Neonatal Herpes Simplex Virus Disease Who Have Completed Standard of Care Treatment With Acyclovir
Record updated
24 June 2025